Composition for diagnosing liver cancer and methods of diagnosing liver cancer and obtaining information for diagnosing liver cancer

Patent metadata

Field	Value
Publication number	US-9518125-B2
Application number	US-201414322570-A
Country	US
Kind code	B2
Filing date	Jul 2, 2014
Priority date	Oct 15, 2013
Publication date	Dec 13, 2016
Grant date	Dec 13, 2016

Abstract

Provided is method of diagnosing liver cancer in a subject, the method comprising contacting a sample from a subject with a substance that specifically binds to transmembrane emp24 domain trafficking protein 2 (TMED2), cluster of differentiation 43 (CD43), or any combination thereof on the surface of a microvesicle; and measuring the level of the substance bound to microvesicles in the sample; and related methods and compositions.

First claim

What is claimed is:

1. A method of diagnosing liver cancer in a subject, the method comprising:
contacting a sample from a subject with a substance that specifically binds to transmembrane emp24 domain trafficking protein 2 (TMED2) on the surface of a microvesicle in the sample to provide a mixture of the sample and the substance, wherein the substance is an anti-TMED2 antibody fixed to a solid support, thereby forming a complex between the anti-TMED2 antibody fixed to the solid support and the TMED2 on the surface of the microvesicle;
separating the complex from the mixture;
measuring the level of a marker for a microvesicle from the complex in the sample, wherein the marker is a surface protein on the microvesicle selected from the group consisting of CD63, CD83, integrin-beta 1 (ITGB1), CD9, CD36, CD81, EpCAM, caveolin, FasL, HLA-DRA, MUC1, ERBB4, GPER, ERBB2, MLANA, and AMHR2;
measuring the level of the marker for a microvesicle in a control sample; and
determining that the subject has a liver cancer when the level of the marker for a microvesicle in the sample is greater than that in the control sample,
wherein the control sample includes a plurality of samples obtained from cirrhosis patients.

2. The method according to claim 1 , wherein the marker for a microvesicle is integrin-β1.

3. The method according to claim 1 , wherein the solid support is a magnetic microparticle or a magnetic nanoparticle.

4. The method according to claim 1 , further comprising lysing the microvesicle in the complex after the separating step and before the measuring step to produce a lysate of the microvesicle.

5. The method according to claim 4 , wherein the measuring step comprises conducting an electrophoresis for the lysate and then western blotting.

6. The method according to claim 5 , wherein the anti-TMED2 antibody is attached to a detectable label.

Assignees

• Samsung Electronics Co Ltd

Inventors

• Yong Ye-Ryoung
• Kang Hyun-Ju
• Kim Ga-Hee
• Park Kyung-Hee
• Park Jong-Myeon

Classifications

• C12Q1/6834 Primary

  Enzymatic or biochemical coupling of nucleic acids to a solid phase · CPC title

• C07K16/2896

  against molecules with a "CD"-designation, not provided for elsewhere · CPC title

• C12Q2563/161

  Vesicles, e.g. liposome · CPC title

• G01N33/586

  Liposomes, microcapsules or cells · CPC title

• C12Q2600/178

  miRNA, siRNA or ncRNA · CPC title